Department of Microbiology, Faculty of Veterinary Medicine, University of Tehran , Tehran , Iran.
Braz J Microbiol. 2012 Jan;43(1):363-70. doi: 10.1590/S1517-838220120001000043. Epub 2012 Jun 1.
Colibacillosis is an important disease in the poultry industry which causes serious economic damages. As it is suggested that vaccination is one of the means to control colibacillosis, we tried to investigate the vaccine potential of a ∆aroA derivative of an O78:K80 avian pathogenic Escherichia coli containing increased serum survival gene. 490 chicks were selected as follows: For assessment of virulence of ∆aroA mutant, 30 chicks were divided into three groups and injected with 0.5ml of PBS or bacterial suspension containing either10(7) colony forming units (CFU) of mutant or parent strains via subcutaneous route. Macroscopic lesions and mortality rate were recorded in different groups during the week after challenge. For assessment of safety and immunogenicity of the ∆aroA mutant, three groups of 20 chicks were vaccinated by aerosol administration of 250 ml of suspension containing 10(8) CFU of mutant strain at days 1 and 14, while the two other groups received PBS or wild type strain. Macroscopic lesions and mortality rate were recorded in different groups until day 21. To determine whether the vaccination is protective against challenges or not, the chickens were vaccinated at days 1 and 14 and challenged intramuscularly with either a homologous or heterologous strains at day 21. Macroscopic lesions and mortality rate were recorded in different groups during the week after challenge. The results revealed that the ∆aroA mutant was slightly virulent, however it was safe and did not cause mortality, lesions or weight loss after vaccination. Antibody responses were similar in the control and mutant groups and vaccination did not induce a significant humoral immunity. The mutant could not protect chickens against both homologous and heterologous challenges. This could be due to several factors such as the high amount of maternal antibodies in the first two weeks of life, and the vaccination procedure.
大肠杆菌病是家禽业中的一种重要疾病,可造成严重的经济损失。鉴于疫苗接种是防控大肠杆菌病的手段之一,本研究旨在评估一株血清存活能力增强的 O78:K80 禽源致病性大肠杆菌 ∆aroA 衍生突变株的疫苗潜力。将 490 只雏鸡分为以下三组:①为评估 ∆aroA 突变株的毒力,30 只雏鸡通过皮下注射途径分别注射 0.5ml PBS 或含 10(7)CFU 突变株或亲本株的细菌混悬液,3 组雏鸡在攻毒后第 1 周内每天观察并记录宏观病变和死亡率;②为评估 ∆aroA 突变株的安全性和免疫原性,3 组 20 只雏鸡通过气溶胶途径分别接种含 10(8)CFU 突变株的混悬液 250ml,另外 2 组雏鸡分别注射 PBS 或亲本株,每组雏鸡在攻毒后第 21 天内每天观察并记录宏观病变和死亡率;③为评估疫苗接种的保护效力,雏鸡于第 1 天和第 14 天肌肉注射接种同源或异源突变株,在攻毒后第 21 天观察并记录宏观病变和死亡率。结果表明,△aroA 突变株的毒力略有减弱,但接种安全,不引起死亡率、病变或体重减轻。对照组和突变株组的抗体反应相似,且疫苗接种不能诱导显著的体液免疫。突变株不能保护鸡免受同源和异源攻毒。这可能是由于雏鸡在生命的前两周内存在大量的母源抗体,以及疫苗接种程序等因素所致。